WO1999055849A1 - Tyrosine phosphatase ia-2, gad and rotavirus vp7 immunity - Google Patents
Tyrosine phosphatase ia-2, gad and rotavirus vp7 immunity Download PDFInfo
- Publication number
- WO1999055849A1 WO1999055849A1 PCT/AU1999/000314 AU9900314W WO9955849A1 WO 1999055849 A1 WO1999055849 A1 WO 1999055849A1 AU 9900314 W AU9900314 W AU 9900314W WO 9955849 A1 WO9955849 A1 WO 9955849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetes
- peptide
- sequence
- cell
- rotavirus
- Prior art date
Links
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title claims description 15
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title claims description 15
- 108700012261 Rotavirus VP7 Proteins 0.000 title claims description 8
- 230000036039 immunity Effects 0.000 title description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 title description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 title description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 52
- 241000702670 Rotavirus Species 0.000 claims abstract description 29
- 229960005486 vaccine Drugs 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 55
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 24
- 230000005867 T cell response Effects 0.000 claims description 23
- 230000004044 response Effects 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 210000004153 islets of langerhan Anatomy 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 230000003278 mimic effect Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 101710169693 Core protein VP7 Proteins 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 102100034091 Receptor-type tyrosine-protein phosphatase-like N Human genes 0.000 description 71
- 101000591210 Homo sapiens Receptor-type tyrosine-protein phosphatase-like N Proteins 0.000 description 66
- 102100037404 Receptor-type tyrosine-protein phosphatase N2 Human genes 0.000 description 32
- 101000738765 Homo sapiens Receptor-type tyrosine-protein phosphatase N2 Proteins 0.000 description 30
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 24
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 24
- 208000015181 infectious disease Diseases 0.000 description 19
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 17
- 238000003556 assay Methods 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 102000054766 genetic haplotypes Human genes 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000005784 autoimmunity Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- 125000001165 hydrophobic group Chemical group 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- -1 sulphenyl halides Chemical class 0.000 description 6
- 108010044226 Class 8 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 241000709687 Coxsackievirus Species 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 101150014889 Gad1 gene Proteins 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010067470 Rotavirus infection Diseases 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 206010014909 Enterovirus infection Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 101710166523 Genome polyprotein Proteins 0.000 description 2
- 101710121996 Hexon protein p72 Proteins 0.000 description 2
- 101000825079 Homo sapiens Transcription factor SOX-13 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 101710168689 Receptor-type tyrosine-protein phosphatase N2 Proteins 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 101710144761 Reverse transcriptase Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100022435 Transcription factor SOX-13 Human genes 0.000 description 2
- 240000006677 Vicia faba Species 0.000 description 2
- 235000010749 Vicia faba Nutrition 0.000 description 2
- 235000002098 Vicia faba var. major Nutrition 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 235000021434 dietary agent Nutrition 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 208000012022 enterovirus infectious disease Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 108010021315 integrin beta7 Proteins 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- JAJQQUQHMLWDFB-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-5-phenylpentanoate Chemical compound OC(=O)CC(O)C(N)CC1=CC=CC=C1 JAJQQUQHMLWDFB-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- CLCPDSJUXHDRGX-UHFFFAOYSA-N 6-(1,3-dihydroxyisobutyl)thymine Chemical compound CC1=C(CC(CO)CO)NC(=O)NC1=O CLCPDSJUXHDRGX-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- OQKYEMHWZYHWBL-UHFFFAOYSA-N 9h-fluoren-1-ylmethanol Chemical class C1C2=CC=CC=C2C2=C1C(CO)=CC=C2 OQKYEMHWZYHWBL-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101150070472 BRRF2 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000761239 Bos taurus Kappa-casein Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 101800001603 Capsid protein C Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101800001847 Core protein precursor Proteins 0.000 description 1
- 241000709673 Coxsackievirus B4 Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710116749 Envelopment polyprotein Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical class CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010064885 HLA-DR3 Antigen Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710843 Japanese encephalitis virus group Species 0.000 description 1
- 201000009758 Kunjin encephalitis Diseases 0.000 description 1
- 208000030510 Kunjin virus infectous disease Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710109125 Major outer capsid protein Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methyl urea Chemical compound CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- 101800001641 NTPase Proteins 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 101800001064 Protein 2C Proteins 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 229940124859 Rotavirus vaccine Drugs 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
- 102100027188 Thyroid peroxidase Human genes 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 101710154918 Trigger factor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000006449 West Nile encephalitis Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 244000000021 enteric pathogen Species 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical class OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- SJFKGZZCMREBQH-UHFFFAOYSA-N methyl ethanimidate Chemical compound COC(C)=N SJFKGZZCMREBQH-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- CLKZWXHKFXZIMA-UHFFFAOYSA-N pyrinuron Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)NCC1=CC=CN=C1 CLKZWXHKFXZIMA-UHFFFAOYSA-N 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000003128 rodenticide Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to T-cell epitopes of tyrosine phosphatase IA-2 and to methods involving the use of these epitopes.
- T-cells Activation of T-cells requires recognition by T-cell receptors of specific, antigenic peptides complexed to major histocompatibility complex (MHC) molecules on the surface of target or antigen-presenting cells (1).
- MHC major histocompatibility complex
- T-cell epitopes "restricted" by the MHC molecule, are potential tools for the diagnosis, monitoring and therapy of infectious, autoimmune and neoplastic disorders.
- pancreatic islet autoantigen in type 1 diabetes is a 106 kD member of the protein tyrosine phosphatase family (2,3) and an integral membrane protein of neuroendocrine secretory granules (4). Circulating autoantibodies that recognise predominantly the cytoplasmic domain of IA-2 can be detected in up to 88% of people with recently-diagnosed type 1 diabetes and in about half of islet-cell antibody (ICA)-positive, first-degree type 1 diabetes relatives in whom they indicate high risk for clinical disease (5, 6).
- ICA islet-cell antibody
- the cytoplasmic domain of IA-2 has 80% sequence identity with another tyrosine phosphatase, IAR (7), also known as IA-2 ⁇ (8) or phogrin (9), which also reacts with antibodies in type 1 diabetes (10).
- IAR (7) also known as IA-2 ⁇ (8) or phogrin (9)
- T-cell proliferative responses to IA-2 were reported to be increased in at-risk relatives and in people with recently-diagnosed type 1 diabetes (11).
- T-cell epitope peptides in autoantigens have potential diagnostic and therapeutic applications and may hold clues to environmental agents that could trigger or exacerbate autoimmune disease.
- the present inventors have identified T-cell epitope peptides within the intracytoplasmic domain of IA-2 and examined them for sequence similarities with microorganisms and dietary proteins as a basis for molecular mimicry.
- the present invention consists in a tyrosine phosphatase IA-2 T-cell epitope, the T-cell epitope having a sequence included within or consisting of a sequence selected from the group consisting of LA- 2 aa685-700 ANMDISTGHMILAYME, IA-2 aa713-728 WQALCAYQAEPNTCAT, IA-2 aa745-760 PYDHARIKLKVESSPS, IA-2 aa787-802 LSHTLADFWQMVWESG, IA-2 aa793-808 DFWQMVWESGCTVIVM, IA-2 aa799-814 WESGCTVIVMLTPLVE, IA-2 aa805-820 VIVMLTPLVEDGVKQC, IA-2 aa841-856 SEHIWCEDFLVRSFYL, IA-2 aa845-860 WCEDFLVRSFYLKNVQ, IA-2 aa847-862 EDFLVRSFYLKNVQTQ
- the present invention consists in a T-cell epitope, the T-cell epitope having a sequence included within or consisting of a sequence selected from the group consisting of IAR aa721-736
- the T-cell epitope has a sequence included within or consisting of the sequence VIVMLTPLVEDGVKQC . In a further preferred embodiment the T-cell epitope has the sequence
- modifications may be made to the peptides of the present invention while still retaining function.
- modifications include having amino acid substitutions compared to the native IA-2 or IAR sequence but which retain certain structural and functional characteristics. These modifications include additions, deletions and substitutions, in particular conservative substitutions. It is intended that peptides including such modifications are within the scope of the present invention.
- modifications of the peptides envisaged include, but are not limited to. modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide synthesis and the use of crosslinkers and other methods which impose conformational constraints on the peptides.
- side chain modifications contemplated by the present invention include, but are not limited to, modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidation with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5'-phosphate followed by reduction with NaBHj.
- modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidation with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2,4,6-trinitrobenzene s
- the guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.
- the carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.
- Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with
- Tyrosine residues may be altered by nitration with tetranitromethane to form 3-nitrotyrosine derivative.
- Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.
- Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid; 2-thienyl alanine and/or D-isomers of amino acids.
- the peptides of the present invention may be derived from IA-2 and IAR. It is, however, preferred that the peptides are produced synthetically using methods well known in the field.
- the peptides may be synthesised using solution synthesis or solid phase synthesis as described, for example, in Chapter 9 entitled “Peptide Synthesis” by Atherton and Sheppard which is included in a publication entitled “Synthetic Vaccines” edited by Nicholson and published by Blackwell Scientific Publications.
- a solid phase support is utilised which may be polystyrene gel beads wherein the polystyrene may be cross-linked with a small proportion of divinylbenzene (e.g.
- polystyrene may be functionalised with chloromethyl or anionomethyl groups.
- cross-linked and functionalised polydimethyl-acrylamide gel is used which may be highly solvated and swollen by DMF and other dipolar aprolic solvents.
- Other supports can be utilised based on polyethylene glycol which is usually grafted or otherwise attached to the surface of inert polystyrene beads. In a preferred form, use may be made of commercial solid supports or resins which are selected from PAL-PEG, PAK-PEG, KA, KR or TGR.
- reversible blocking groups which have the dual function of masking unwanted reactivity in the ⁇ -amino, carboxy or side chain functional groups and of destroying the dipolar character of amino acids and peptides which render them inactive.
- Such functional groups can be selected from t-butyl esters of the structure RCO-OCMe 3 -CO-NHR which are known as t-butoxy carboxyl or ROC derivatives.
- Use may also be made of the corresponding benzyl esters having the structure RCO-OCH 2 -C 6 H 5 and ethanes having the structure C 6 H 5 CH 2 OCO-NHR which are known as the benzyloxycarbonyl or Z-derivatives.
- Use may also be made of derivatives of fluorenyl methanol and especially the fluorenyl- me thoxy carbonyl or Fmoc group.
- Each of these types of protecting group is capable of independent cleavage in the presence of one other so that frequent use is made, for example, of BOC-benzyl and Fmoc-tertiary butyl protection strategies.
- esters of triazine DHBT (as discussed on page 215-216 of the abovementioned Nicholson reference) also may be used.
- Other acylating species are formed in situ by treatment of the carboxylic acid (i.e. the Na-protected amino acid or peptide) with a condensing reagent and are reacted immediately with the amino component (the carboxy or C-protected amino acid or peptide).
- Dicyclohexylcarbodiimide the BOP reagent (referred to on page 216 of the Nicholson reference), O'Benzotriazole-N, N, N'N'-tetra methyl-uronium hexaflurophosphate (HBTU) and its analogous tetrafluroborate are frequently used condensing agents.
- the attachment of the first amino acid to the solid phase support may be carried out using BOC-amino acids in any suitable manner. In one method BOC amino acids are attached to chloromethyl resin by warming the triethyl ammonium salts with the resin. Fmoc-amino acids may be coupled to the p-alkoxybenzyl alcohol resin in similar manner. Alternatively, use may be made of various linkage agents or "handles" to join the first amino acid to the resin. In this regard, p-hydroxymethyl phenylactic acid linked to aminomethyl polystyrene may be used for this purpose.
- the present invention consists in a method of assessing the risk of an individual developing type 1 diabetes.
- the method comprises measuring responsiveness of T cells of individuals at-risk, either by being a relative of an individual with type 1 diabetes, or with other immune markers of sub-clinical disease eg circulating autoantibodies to islet antigens, or by being exposed to a potential environmental trigger factor (eg non-exclusively virus, dietary agent, toxin).
- a potential environmental trigger factor eg non-exclusively virus, dietary agent, toxin.
- T-cell responses to the peptides are measured non-exclusively by the number of cells with activation markers or with specific levels of activation markers (eg CD69, CD44, CD25), numbers of cells with specific cytokines (eg interferon- ⁇ , IL-4, IL-2, IL-10, TNF- ⁇ and others) or the levels of cytokines produced in or secreted by the cells, or by proliferation of T cells. All measurements are in comparison to T-cell responses from the same individual without the peptides, and in comparison to responses from healthy controls. Elevated (or changing) responses on any of these, or other appropriate, measures of T-cell responses to the peptides on one (or multiple) occasion/s may indicate the level of risk of type 1 diabetes.
- the present invention consists in a method of therapy for the prevention of the onset of type 1 diabetes in those assessed to be at-risk.
- the assessment of risk may be determined either by the method of the present invention, or by T-cell responses to whole molecules or peptides from other type 1 diabetes-associated autoantigens (eg insulin, proinsulin, glutamic acid decarboxylase), and/or by the presence of antibodies to islet autoantigens.
- type 1 diabetes-associated autoantigens eg insulin, proinsulin, glutamic acid decarboxylase
- the therapeutic use of the peptides is to induce tolerance to protect against or ameliorate the symptoms associated with type 1 diabetes, by the oral, aerosol, intranasal or other mode of administration of the peptides to mucosal surfaces, or by other appropriate methods of administration eg non-exclusively transdermally, subcutaneous or intravenous.
- the presentation of soluble protein antigen to mucosal surfaces classically via the oral route, results in selective suppression of antigen-specific T-cell responses, and has been associated with the deviation of immunity away from pro-inflammatory Thl T-cell responses to antibody (Th2) responses.
- Th2 Th2
- Regulatory cells, and, at higher antigen doses, T-cell anergy and T-cell deletion have been shown to be induced. Aerosol inhalation of an autoantigen (insulin)in an animal model for type 1 diabetes was effective in reducing islet cell pathology and incidence of diabetes(12).
- the present invention consists in a method of therapy for the prevention of the re-establishment of type 1 diabetes in those who have received a pancreatic or islet-cell transplant to alleviate their pre-existing type 1 diabetes.
- the therapy is intended to prevent, reduce or otherwise ameliorate the development of T-cell responses to the autoantigens in the graft, which could lead to its destruction.
- the method of administration is as in the above paragraph.
- the present inventors have identified T-cell epitope peptides in the intracytoplasmic domain of the type 1 diabetes autoantigen, tyrosine phosphatase IA-2, whose sequence analysis suggests that immunity to rotavirus (whose VP7 sequence mimics epitopes in both IA-2 and GAD) could predispose to type 1 diabetes by activating crossreactive T cells.
- RV infection may trigger or exacerbate islet autoimmunity, on the HLA-DR4 background.
- rotavirus vaccines currently undergoing trials are live viruses containing the VP7 leader sequence, these findings have implications for development of safe rotavirus vaccines to protect against islet autoimmunity and prevent the development of type 1 diabetes.
- the present invention consists in a vaccine composition for use in raising an immune response in a subject directed against rotavirus, the composition comprising a plurality of antigens including at least one rotavirus VP7 antigen wherein the sequence of the rotavirus VP7 antigen is modified such that at least one of the sequences which mimic one or more of the epitopes selected from the group consisting of ILLQYWKSF, ILLNYVRKTF and VrVMLTPLVED are deleted or modified such as to remove or ameliorate mimicry.
- the composition includes at least one attenuated strain of rotavirus, the rotavirus nucleic acid encoding VP7 being modified such that the expressed VP7 antigen is modified such that at least one of the sequences which mimic one or more of the epitopes selected from the group consisting of ILLQYWKSF.
- ILLNYVRKTF and VTVMLTPLVED are deleted or modified such as to remove or ameliorate mimicry.
- sequence which mimics ILLQYWKSF or ILLNYVRKTF is deleted.
- aa 17 A, a small hydrophobic residue, replaces the Pi anchor for binding to DR4, DQ8 aa 18: A, a small hydrophobic residue replaces a T-cell receptor contact residue (TCR-CR) aa 21: A, a small hydrophobic residue replaces a TCR-CR for both
- DQ8 aa 24 H, a weaker basic residue, replaces K which is conserved in all rotavirus strains and in both GAD65 and GAD67 epitopes aa 40: A, a small hydrophobic residue, replaces Pi anchor for binding to DR4, DQ8 aa 44: A, a small hydrophobic residue replaces a TCR-CR for DR4, and the P4 anchor for binding DQ8 aa 45 : F, a bulky hydrophobic residue, present in other Gl VP7 sequences in this position, replaces the P6 anchor for binding to DR4, and a TCR-CR for DQ8.
- the present invention consists in a ligand for antigen-specific T lymphocytes, the ligand comprising a multimeric peptide-MHC complex in which the peptide is selected from the group consisting of ANMDISTGHMILAYME, WQALCAYQAEPNTCAT, PYDHARIKLKVESSPS, LSHTIADFWQMVWESG, DFWQMVWESGCTVTVM, WESGCTVIVMLTPLVE, VIVMLTPLVEDGVKQC, SEHIWCEDFLVRSFYL, WCEDFLVRSFYLKNVQ, EDFLVRSFYLKNVQTQ, DFRRKVNKCYRGRSCP, YILIDMVLNRMAKGVK, FEFALTAVAEEVNAIL, SNMDISTGHMILSYME, WEALCAYQAEPNSSFV, TYDHSRVLLKAENSHS, LPATVADFWQMVWESG, DFWQMVWESGCWIVM, WESGCWIVMLTPLAE, VIVMLTPLAENGVR
- the peptide is VIVMLTPLVEDGVKQC or VIVMLTPLVED.
- the multimer is a dimer or tetramer.
- the ligand is provided with a detectable label.
- the detectable label may be any one of a number of any such labels well known in the art such as biotin, a fluorophor, or radioisotope.
- the ligand of this aspect of the present invention can be used in assessing the risk of an individual of developing type 1 diabetes.
- the method would involve measuring the numbers of antigen-specific T lymphocytes in a sample from the individual. Where the ligand is provided with a label this could be done by flow cytometry. Further, as would be readily appreciated the ligand of the present invention could be used in vivo for imaging.
- Fig 1 Summary of identified T-cell epitope peptides in tyrosine phosphatase IA-2. Bolded boxes contain sequences common to overlapping epitope peptides; unbolded boxes contain epitope peptides presented by both
- Fig 2 Proliferative T cell response to IA-2 peptides in subjects at risk for type 1 diabetes; DR4DQ8 homozygous subjects (2a); DR3DQ2 homozygous subjects (2c); heterozygous subjects (2b).
- Fig 3 T cell responses to peptides in tyrosine phosphatase IA-2 for each group of subjects.
- Fig 4 RV Ab and islet Ab responses over 5 years in sibs at-risk for type 1 diabetes.
- A sib 1, female, HLA-DR3,4;
- B sib 2, male, HLA-DR1,4.
- Peripheral blood was obtained from six at-risk, islet cell antibody (ICA) positive first-degree relatives of people with type 1 diabetes (4 male, 2 female, mean age 28.5 ⁇ 15.0, range 10-50) and two healthy control subjects (2 males, ages 30, 48).
- Subjects were selected for type 1 diabetes-associated HLA haplotypes, ie DR4-DQ8 homozygous (two at-risk relatives, one control), DR3-DQ2 homozygous (two at-risk relatives, one control) and DR4-DQ8/DR3-DQ2 heterozygous (two at-risk relatives). All relatives had antibodies to IA-2.
- both DR4-DQ8 homozygous relatives developed clinical type 1 diabetes and the first-phase insulin release in response to intravenous glucose in both DR3-DQ2 homozygous relatives fell to below the first percentile, indicating imminent clinical disease.
- the study was approved by the Ethics Committee, and conducted with informed consent.
- HLA-DR and DQ types were determined by sequence-specific oligotyping, following the International Histocompatibility Workshop protocol.
- Each peptide was dissolved in 100/xl 40% acetonitrile in degassed phosphate buffered saline (PBS) and shaken at 4 C overnight, checked for solubility, sonicated in an immersion sonicator for up to 60 min at room temperature (RT) if necessary, then diluted to 1 mg/ml in PBS.
- PBS degassed phosphate buffered saline
- RT room temperature
- HLA-DR4 binding Peptide binding to purified DR4(*0401) was measured directly by a competition enzyme linked immunosorbant assay, as previously described (15,16).
- PBMC peripheral blood mononuclear cells
- RPMI 1640 heparinised venous blood by Ficoll-Hypaque density centrifugation, washed twice in RPMI 1640 medium and diluted to 10 6 cells/ml in RPMH640 medium containing 10% autologous serum, 20 mM Hepes and 10 "5 M 2-mercaptoethanol (complete medium).
- Two x 10 5 cells were added in 200 ⁇ l of complete medium to each well of freshly- thawed, peptide-containing 96-well trays. Each peptide was tested at lO ⁇ g/ml in replicates of 12.
- each tray contained six wells without antigen (basal) and six wells with 1.8 Lyons flocculating units (Lfu)/ml of preservative-free tetanus toxoid (Commonwealth Serum Laboratories, Melbourne); the last row of each tray contained six wells with 0.18 Lfu of tetanus toxoid and six wells without antigen.
- T-cell responses to peptides approximate a Poisson rather than a normal distribution
- proliferation was expressed as the % positive of the 12 replicate wells.
- Positive wells were defined as having cpm >mean + 2 SD of the 12 basal wells for that plate.
- a T-cell response to a peptide was defined as positive wells >_40%; this threshold was the mean + 2SD of the 136 responses of the controls to all peptides (mean 6%, SD 17%).
- T-cell epitopes were defined as being within peptides that elicited a response in two at-risk relatives with the same HLA haplotype, eg both DR4-DQ8 homozygotes, or one DR4-DQ8 homozygote and at least one DR3-DQ2/DR4-DQ8 heterozygote.
- the reproducibility of T-cell proliferation to tetanus (1.8 Lfu/ml) was tested by repeat assays weekly for four weeks in three subjects; intra-assay CVs ranged from 13.1 to 18.9 % and the inter-assay CV from 14.2 to 26.2%.
- IAA IAA were assayed by fluid-phase 125 I-insulin precipitation (17). Results were expressed as percent of total counts precipitated.
- the control range (mean + 2 SD) ⁇ 5.5%, was derived from 190 healthy children (mean age 9.7; range 4.9-15.5 years).
- the inter-assay coefficient of variation (COV) is 16%.
- GADAb and IA-2Ab were assayed by precipitation of 35S-methionine labelled recombinant human proteins and results were expressed as arbitrary units, described elsewhere (6).
- the control range for GADAb derived by receiver operator curve (ROC) analysis of 246 control subjects and 135 newly-diagnosed patients is ⁇ 5U, with an inter-assay COV of 21%. In the international GADAb proficiency test #2, the assay scored 100% for sensitivity, specificity, validity and consistency.
- the control range for IA2Ab, derived by ROC analysis of 145 control subjects and 94 newly-diagnosed patients is ⁇ 3 U, with an inter-assay COV of 34%.
- RVA and RVG were measured initially at a serum dilution of 1:100 by direct enzyme immunoassay (EIA), described previously for RVA in secretions (18,19). Sera were also tested at 1:500 as necessary. Optimal dilutions of reagents determined by chequerboard titration were dispensed in 100 ul aliquots. SAll RV antigen and MA104 cell control antigen were prepared as previously (18). EIA antigens diluted in 0.06M sodium carbonate-bicarbonate buffer pH 9.6 were adsorbed to microtiter plate wells (NUNC Maxisorp) for 2 h at 37°C.
- EIA direct enzyme immunoassay
- CBVM were measured by EIA (16) in 82 sera, 47 with significant increases in RVA or RVG, as controls for specificity of association between RV and islet Ab.
- the assay detects homotypic responses that become heterotypic (ie recognize multiple serotypes of CBV) with increasing age (20).
- Sera at 1:400 dilution were first screened against pooled antigens from CBV serotypes 4 and 5; positive sera were retested with individual antigens. The cut-off was the mean+ 3SD of 10 known negative serum samples/tray.
- the optimum serum dilution (1:400) was derived from previous titrations to 1:10,000, and specificity established by demonstrating no crossreactivity with sera positive for antibodies to Epstein-Barr, measles, mumps and hepatitis A viruses, Mycoplasma pneumoniae and rheumatoid factor.
- Thyroid peroxidase antibodies TPOAb
- TPOAb were measured with the ELI test R anti-TPO kit (Henning Berlin GMBH)
- ANA Anti-nuclear antibodies
- the distribution of the mean log OR expected if there was no association (null hypothesis) was derived by 1000 permutations of the positions of the scores of 1 and 0 for islet and RV Ab in each child, calculating the mean log OR at each permutation. The experimental mean log OR was then compared to the distribution of the mean log ORs from the permutations to determine the probability of association (25).
- peptides from aa 799, 805, 841, 847, 919) elicited responses in the DR3-DQ2 homozygous relatives, and the first four of these also in the matched control.
- peptide EDFLVRSFYLKNVQTQ (aa 847-862) elicited responses in both DR3-DQ2 and DR4-DQ8 homozygous controls, as well as in one DR3-DQ2 homozygous, one heterozygous and both DR4-DQ8 homozygous at-risk relatives.
- VIVMLTPLVEDGVKQC had sequence identities of 75-45% and similarities of 100-64% over 8-11 aa to sequences within the VP7 protein of rotavirus (serotype G3, strain P) and lesser identity to the Gl and G2 subtypes (Table 3). VIVMLTPLVEDGVKQC also has sequence identities with the capsid protein C of Dengue flavivirus, the major capsid protein of human cytomegalovirus, the haemagglutinin proteins of canine distemper virus (known to infect humans) and the closely-related measles virus, and the E2 protein of hepatitis C virus. It also had 50% identity and 71% similarity over 14 aa with the ELI 1338 protein of the bacterium Haemophilus influenzae. Most of the sequence similarities were in the region of overlap,
- VIVMLTPLVE (aa 805-814), with the preceding epitope peptide (aa 799-814).
- the rotavirus VP7 protein also had 75% identity and 92% similarity over 12 aa (aa 18-29) (or 75% and 100% over 9 aa) to GAD65 (aa 117-128), and GAD67 (aa 123-134) (Tables 4 & 5).
- Peptide aa 685-700 had 56-71% identity and 78-86% similarity to the
- BTRFl and BRRF2 proteins of Epstein-Barr virus and 50% identity and 100% similarity over 10 aa to the genome polyprotein of rhinovirus 14. the common cold virus (Table 1).
- Peptide aa 787-802 had 58% identity and 75% similarity over 12 aa to the M polyprotein precursor of hantavirus, and 71% identity and similarity over 7 aa to sequences within the genome polyprotein of other members of the flavivirus family, ie Japanese encephalitis, Kunjin, West Nile and Murray Valley encephalitis viruses. Most of the sequence similarities were in the region of overlap DFWQMVWESG (aa 793-802) with the succeeding epitope peptide (aa 793-808).
- Peptide aa 841-856 had 64% identity and 82% similarity over 11 aa to NADH ubiqinone reductase proteins in wheat and broad beans, and epitope peptide aa 919-934 had 60% identity and 80% similarity over 10 aa to kappa casein in cow's milk. Most of the sequence similarities were in the region of overlap, EDFLVRSFYL (aa 847-856), with the two succeeding epitope peptides (aa 845-860, 847-856).
- Peptide aa 919-934 had 63% identity and 88% similarity over 8 aa to the surface glycoprotein of Herpes simplex virus.
- Peptide aa 959-974 had 67% identity and 78% similarity over 9 aa to the major capsid protein of cytomegalovirus (HHV5) and Herpes saimiri virus (which can infect human lymphocytes), and 50% identity and 70% similarity over 10 aa to replication protein El of papilloma virus strains 28 and 18. It also had 45% similarity and 73% similarity over 11 aa to the E2L polyprotein of vaccinia and variola (HHV6) viruses.
- IAA, GADAb and IA-2Ab appeared at 10 ⁇ 21(mean+sd), 22 ⁇ 17 and 19+14 months respectively. Not all islet Ab appeared in all infants, but IAA first appeared with an increase in RV Ab in 13/21 (62%), GADAb in 10/20 (50%) and IA-2Ab 12/14 (86%) (eg Fig 4).
- TPO Ab measured in 27 concordant islet/RV Ab events were increased only once (from a raised level of 190 to 560 units), and were not increased in the non-concordant events; furthermore, ANA were not detected in concordant islet RV Ab events.
- RVA and RVG decreased a mean of 57% and 40% respectively, whereas GADAb (7%) and LA-2Ab (0%) were unchanged.
- the HLA-DR3 susceptibility haplotype was present in only 4/17 (24%) of the former concordant compared to 7/10 (70%) of the latter discordant infants (p ⁇ 0.05).
- HLA-DQ2-linked DR alleles (DR3 and DR7) were present in 6/17 (35%) concordant compared to 9/10 (90%) of discordant infants (p ⁇ 0.02).
- GAD65 islet autoantigen glutamic acid decarboxylase 65
- P2C protein of Coxsackievirus B4 which share 59% identity and 76% similarity over 17 aa (36).
- GAD65 islet autoantigen glutamic acid decarboxylase 65
- This peptide from GAD65 elicits T-cell responses in humans with type 1 diabetes (29) and in the non-obese diabetic (NOD) mouse model (37).
- T-cell responses to Coxsackie virus B strain unstated have been reported in recently-diagnosed type 1 diabetes (21).
- IgM responses to Coxsackievirus (44) and T-cell responses to both Coxsackievirus and adenovirus were higher in people at diagnosis than in controls.
- the dominant IA-2 epitope peptide aa 805-820 has high identity and similarity over 8-11 aa to sequences within several viruses.
- the nonamer in this peptide predicted to bind to DR4 (14) is VIVMLTPLV.
- TCR-CR T-cell receptor contact residues
- GAD 65 aa 108-137
- rotaviral VP7 a sequence similarity between GAD 65 and rotaviral VP7 protein, although they could not elicit increased T-cell responses to whole rotavirus (strain unstated) in people with recently-diagnosed type 1 diabetes.
- the cited GAD65 sequence contains a T-cell epitope peptide MNILLQYWKSFDRST (aa 115-130, with 88% homology to GAD67, aa 121-136), in mice transgenic for human HLA-DR4 (47).
- This epitope aa 115-129
- the predicted DR4-binding nonamer within the GAD65 peptide is ILLQYWKS, and for VP7 is
- ILLNYVLKS in GAD 67 the equivalent region is ILLNYVRKT.
- GAD65 therefore has 100% similarity and identity with VP7 in the potential TCR-CR (Table 4).
- the region of VP7 containing both sequence similarities is immunologically interesting. It contains many hydrophobic potential anchor residues for HLA class II molecules, and an epitope for cytotoxic T cells in C57/B16 mice immunized with rotavirus (48,49), adjacent to the sequences with similarity to GAD65 and IA-2.
- the GAD and IA-2 similarities raise the interesting possibility that rotavirus infection could simultaneously activate T cells to two type 1 diabetes autoantigens (see also below).
- Rotavirus is a major enteric pathogen of early childhood (50) that causes regular winter outbreaks of gastroenteritis in daycare centres. Children can have multiple infections by different serotypes. Early-age daycare was found to confer increased risk for type 1 diabetes (51). consistent with a link between rotavirus and type 1 diabetes. Furthermore, the most marked increase in type 1 diabetes incidence over the last decade (11%/yr) has occurred in the 0-4 year old age group(62).
- VP7 the major outer capsid protein of RV
- VP7 the major outer capsid protein of RV
- VP7 is an important determinant of virulence and induces virus-neutralizing antibodies (50).
- the elimination of RV following infection is predominantly due to T cells (52).
- Proliferative CD4 T-cell responses have been detected in humans within 4-6 weeks following rotavirus re-infection (53).
- CD4 T cells were of the CD45RA negative (memory), ⁇ 4 ⁇ 7 integrin-high subset, indicating that gastrointestinal immune responses generate ⁇ 4 ⁇ 7 positive T-cell memory.
- GAD-responsive T cells from people with recently-diagnosed type 1 diabetes are ⁇ 4 ⁇ 7 positive (84) and T cells in the early phase of insulitis in NOD mice are ⁇ 7-integrin high (55).
- RV may directly infect islets. This possibility is supported by reports of pancreatitis following rotavirus infection (57,58), and by the fact that rotavirus is a related to reovirus, which can infect human (59) and mouse (60) islets.
- IA-2 epitope peptide aa 919-934 has 60% identity and 80% similarity over 10 aa, that include the predicted DR4 binding nonamer ILIDMVLNR, with bovine kappa casein YIPIQYVLSR (aa 26-35), although the similarity of the potential TCR-CR is only 40%.
- T-cell responses to whole casein have been reported in type 1 diabetes (61) but the role of bovine milk proteins as potential aetiologic agents in type 1 diabetes is controversial (62).
- Peptide aa 841-856 contains a DR4 binding motif WCEDFLVRS (cf VLNDFLVRS in wheat and beans) and a predicted DQ8 binding motif IWCEDFLVRS (cf RVLNDFLVRS in wheat and beans).
- WCEDFLVRS cf VLNDFLVRS in wheat and beans
- IWCEDFLVRS cf RVLNDFLVRS in wheat and beans
- the class II MHC molecule of NOD mice, I-A8 7 is the structural counterpart of human DQ8(*0302), and NOD mice fed casein supplement (Harrison LC, unpublished), wheat flour and to a lesser extent soya bean meal (63), have an accelerated onset of diabetes.
- the present inventors have identified T-cell epitope peptides in the intracytoplasmic domain of the type 1 diabetes autoantigen, tyrosine phosphatase IA-2, whose sequence analysis suggests that immunity to rotavirus (whose VP7 sequence mimics epitopes in both IA-2 and GAD) and possibly other viruses and dietary proteins, could predispose to type 1 diabetes by activating crossreactive T cells.
- HHV human herpes virus
- t potential anchor residues for binding to DR4 and DQ8 are denoted by x.
- RVG 20980 >100000 RVG 50290 67083
- Islet cell antigen 512 is a diabetes-specific islet autoantigen related to tyrosine phosphatases. / Immunol 152: 3183-3188.
- IA-2 and IA-2 b are major autoantigens in type 1 diabetes and the precursors of the 40 kDa and 37 kDa tryptic fragments. JAutoimmun 9: 677-672.
- Mucosa-associated lymphocytes accumulate early in the pancreas of NOD mice and show aberrant recirculation behaviour. Diabetes 45: 1173-1180.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU33999/99A AU3399999A (en) | 1998-04-27 | 1999-04-27 | Tyrosine ia-2, gad and rotavirus vp7 phosphatase immunity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP3209A AUPP320998A0 (en) | 1998-04-27 | 1998-04-27 | Tyrosine phosphatase IA-2 T-cell epitopes |
AUPP3209 | 1998-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999055849A1 true WO1999055849A1 (en) | 1999-11-04 |
WO1999055849A8 WO1999055849A8 (en) | 2000-05-25 |
Family
ID=3807466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1999/000314 WO1999055849A1 (en) | 1998-04-27 | 1999-04-27 | Tyrosine phosphatase ia-2, gad and rotavirus vp7 immunity |
Country Status (2)
Country | Link |
---|---|
AU (1) | AUPP320998A0 (en) |
WO (1) | WO1999055849A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063702A1 (en) * | 1999-04-21 | 2000-10-26 | Zycos Inc. | Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
WO2001042281A1 (en) * | 1999-12-06 | 2001-06-14 | Hôpital Sainte-Justine | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
US6562943B1 (en) | 1999-04-21 | 2003-05-13 | Zycos, Inc. | Peptide epitopes recognized by disease promoting CD4+ T lymphocytes |
EP3221344A2 (en) * | 2014-11-21 | 2017-09-27 | Immusant Inc. | Peptides for use in treatment and diagnosis of type 1 diabetes |
-
1998
- 1998-04-27 AU AUPP3209A patent/AUPP320998A0/en not_active Abandoned
-
1999
- 1999-04-27 WO PCT/AU1999/000314 patent/WO1999055849A1/en active Application Filing
Non-Patent Citations (5)
Title |
---|
DIABETES, (1997), Volume 46, ZHANG B. et al., "Autoantigens to IA-2 in IDDM: Location of Major Antigenic Determinants", pages 40-43. * |
JOURNAL OF IMMUNOLOGY, (1996), Volume 157, LAMPASONA V. et al., "Autoantibodies in Insulin-Dependent Diabetes Recognize Distinct Cytoplasmic Domains of the Protein Tyrosine Phosphatase-Like IA-2 Autoantigen", pages 2707-2711. * |
MOLECULAR MEDICINE, (1997), Volume 29, HONEYMAN M.C. et al., "Strategies for Identifying and Predicting Islet Autoantigen T-Cell Epitopes in Insulin-Dependent Diabetes Mellitus", pages 401-404. * |
MOLECULAR MEDICINE, (April 1998), Volume 4, HONEYMAN M.C. et al., "T-Cell Epitopes in Type 1 Diabetes Autoantigen Tyrosine Phosphatase IA-2: Potential for Mimicry with Rotavirus and other Environmental Agents", pages 231-239. * |
NATURE BIOTECHNOLOGY, (October 1998), Volume 16, HONEYMAN M.C. et al., "Neural Network-Based Prediction of Candidate T-Cell Epitopes", pages 966-969. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063702A1 (en) * | 1999-04-21 | 2000-10-26 | Zycos Inc. | Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
US6562943B1 (en) | 1999-04-21 | 2003-05-13 | Zycos, Inc. | Peptide epitopes recognized by disease promoting CD4+ T lymphocytes |
US7173108B2 (en) | 1999-04-21 | 2007-02-06 | Mgi Pharma Biologics, Inc. | Peptide epitopes recognized by disease promoting CD4+ T lymphocytes |
US7408029B2 (en) | 1999-04-21 | 2008-08-05 | Mgi Pharma Biologics, Inc. | Peptide epitopes recognized by disease promoting CD4+ T lymphocytes |
US7408031B2 (en) | 1999-04-21 | 2008-08-05 | Mgi Pharma Biologics, Inc. | Peptide epitopes recognized by disease promoting CD4+ T lymphocytes |
WO2001042281A1 (en) * | 1999-12-06 | 2001-06-14 | Hôpital Sainte-Justine | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
US7442763B2 (en) | 1999-12-06 | 2008-10-28 | Hopital Sainte-Justine | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
EP3221344A2 (en) * | 2014-11-21 | 2017-09-27 | Immusant Inc. | Peptides for use in treatment and diagnosis of type 1 diabetes |
US10473647B1 (en) | 2014-11-21 | 2019-11-12 | Immusant, Inc. | Peptides for use in treatment and diagnosis of type 1 diabetes |
Also Published As
Publication number | Publication date |
---|---|
WO1999055849A8 (en) | 2000-05-25 |
AUPP320998A0 (en) | 1998-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103648527B (en) | Synthetic peptide-based marker vaccine and diagnostic system for effective control of porcine reproductive and respiratory syndrome (PRRS) | |
Poole et al. | Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments | |
CA1340735C (en) | Htlv-iii envelope peptides | |
US7084247B2 (en) | Identification of self and non-self antigens implicated in autoimmune diseases | |
DK172035B1 (en) | A synthetic polypeptide, a synthetic polypeptide innoculum, an antibody, a process for testing anti-EBNA antibodies in a body sample, and a diagnostic system | |
Wylie et al. | Participation of the major histocompatibility complex in antibody recognition of viral antigens expressed on infected cells. | |
Glass et al. | MHC class II restricted recognition of FMDV peptides by bovine T cells. | |
Balayan | Natural hosts of hepatitis A virus | |
JPS60500673A (en) | Amino acid sequence with antigenic activity | |
KR20130041185A (en) | Designer peptide-based pcv2 vaccine | |
US20200164060A1 (en) | Herpes simplex virus vaccine epitopes specifically recognized by tissue resident memory t cells | |
US6232522B1 (en) | Non-human animal model for systemic lupus erythematosis | |
Marttila et al. | Responses of coxsackievirus B4-specific T-cell lines to 2C protein—characterization of epitopes with special reference to the GAD65 homology region | |
JP3307636B2 (en) | Assays and treatments for autoimmune diseases | |
Barnett et al. | I-Ad restricted T cell recognition of influenza hemagglutinin. Synthetic peptides identify multiple epitopes corresponding to antibody-binding regions of the HA1 subunit. | |
JPS63500659A (en) | Anti-rabies compositions and methods based on synthetic peptides | |
Choudhuri et al. | Immunological cross‐reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis | |
CN114276422A (en) | Novel coronavirus S protein polypeptide antigen and application thereof | |
Varela-Calvino et al. | T-Cell reactivity to the P2C nonstructural protein of a diabetogenic strain of coxsackievirus B4 | |
Roehrig et al. | Enhancement of the antibody response to flavivirus B-cell epitopes by using homologous or heterologous T-cell epitopes | |
WO1999055849A1 (en) | Tyrosine phosphatase ia-2, gad and rotavirus vp7 immunity | |
ES2143996T5 (en) | PEPTIDIC ANTIGENS OF HCV AND PROCEDURE FOR THE DETERMINATION OF HCV. | |
Myoung et al. | Anticapsid immunity level, not viral persistence level, correlates with the progression of Theiler's virus-induced demyelinating disease in viral P1-transgenic mice | |
Dyrberg et al. | Immunological cross-reactivity between mimicking epitopes on a virus protein and a human autoantigen depends on a single amino acid residue | |
Stoyloff et al. | Neutralization of Borna disease virus depends upon terminal carbohydrate residues (α-D-Man, β-D-GlcNAc) of glycoproteins gp17 and gp94 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 44/99 UNDER (54) THE TITLE IN ENGLISH SHOULD READ "TYROSINE PHOSPHATASE IA-2, GAD AND ROTAVIRUS VP7 IMMUNITY" |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |